MedTrace Logo

Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda

NCT00599326 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2014-02-10

Study results available
· View outcomes & findings →

Summary

To determine the efficacy and tolerability of deferasirox in the treatment of Porphyria Cutanea Tarda.

Primary objective - the elimination of all blistering within 6 months of treatment.

Secondary objective - decrease in total body iron levels.

Conditions

  • Porphyria Cutanea Tarda

Interventions

DRUG

Deferasirox

250 mg of deferasirox once daily for 6 months

Sponsors & Collaborators

Principal Investigators

  • Amit Pandya, M.D. · UT Southwestern Medical Center at Dallas - Department of Dermatology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00599326 on ClinicalTrials.gov